Search results
Results from the WOW.Com Content Network
The area provides a reference unit, for example in reference ranges for urine tests. [3]Used for grading of soft tissue tumors: Grading, usually on a scale of I to III, is based on the degree of differentiation, the average number of mitoses per high-power field, cellularity, pleomorphism, and an estimate of the extent of necrosis (presumably a reflection of rate of growth).
In a clinical setting, and where the intention is only to compare observations rather than to state an index, informal alternatives may be used: for example "12 mitotic figures are noted per 10 high power [microscopic] fields" in contrast with "4 mitotic figures noted per 50 high power fields." (Mitotic figures are cells recognisably in mitotic ...
Usually the number of mitotic figures is expressed as the total number in a defined number of high power fields, such as 10 mitoses in 10 high power fields. Since the field of vision area can vary considerably between different microscopes, the exact area of the high power fields should be defined in order to compare results from different studies.
Mitotic count per 10 high-power fields (HPFs) [21] Area per HPF Score 0.096 mm 2 [notes 1] 0.12 mm 2 [notes 1] 0.16 mm 2 [notes 1] ... As a result, a given stage may ...
In histopathology, the mitosis rate (mitotic count or mitotic index) is an important parameter in various types of tissue samples, for diagnosis as well as to further specify the aggressiveness of tumors. For example, there is routinely a quantification of mitotic count in breast cancer classification. [74]
This page was last edited on 26 January 2024, at 11:14 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
[10] During early G1, there are three transcriptional repressors, known as pocket proteins, that bind to E2F transcription factors. The E2F gene family is a group of transcription factors that target many genes that are important for control of the cell cycle, including cyclins, CDKs, checkpoint regulators, and DNA repair proteins.
HPF Phase 1 applied Rosetta v4.2x software on the human genome and 89 others, starting in November 2004. Phase 1 ended in July 2006. Phase 1 ended in July 2006. HPF Phase 2 (HPF2) applies the Rosetta v4.8x software in higher resolution, "full atom refinement" mode, concentrating on cancer biomarkers (proteins found at dramatically increased ...